U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 4

1.
Figure 4

Figure 4. From: Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial.

Change in MADRS scores over 2 weeks by BPD subtype (I vs. II; n=15).

Carlos A Zarate, et al. Biol Psychiatry. ;71(11):939-946.
2.
Figure 2

Figure 2. From: Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial.

(A) Proportion of patients responding (50% improvement on MADRS) to ketamine and placebo from 40 minutes to Day 14 post-infusion. (B) Proportion of patients experiencing remission (MADRS <10) to ketamine and placebo from 40 minutes to Day 14 post-infusion.

Carlos A Zarate, et al. Biol Psychiatry. ;71(11):939-946.
3.
Figure 1

Figure 1. From: Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial.

Change in MADRS, 17-item HDRS, and BDI scores over 2 weeks (n=15). Values are expressed as generalized least square means and standard errors for the Intent to Treat (ITT) analysis. *indicates p<0.05, ** p <0.01, *** p <0.001.

Carlos A Zarate, et al. Biol Psychiatry. ;71(11):939-946.
4.
Figure 3

Figure 3. From: Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial.

Change in suicidal thoughts (suicide item from MADRS) over 2 weeks. Values are expressed as generalized least squares means and standard errors for the Intent to Treat (ITT) analysis. *indicates p <0.05, ** p <0.01, *** p <0.001.

Carlos A Zarate, et al. Biol Psychiatry. ;71(11):939-946.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center